AU2005259786B2 - Method of detecting mutations in the gene encoding cytochrome P450-2C9 - Google Patents
Method of detecting mutations in the gene encoding cytochrome P450-2C9 Download PDFInfo
- Publication number
- AU2005259786B2 AU2005259786B2 AU2005259786A AU2005259786A AU2005259786B2 AU 2005259786 B2 AU2005259786 B2 AU 2005259786B2 AU 2005259786 A AU2005259786 A AU 2005259786A AU 2005259786 A AU2005259786 A AU 2005259786A AU 2005259786 B2 AU2005259786 B2 AU 2005259786B2
- Authority
- AU
- Australia
- Prior art keywords
- seq
- cyp2c9
- primers
- pcr
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 44
- 108090000623 proteins and genes Proteins 0.000 title claims description 32
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 title claims description 27
- 101710101953 Cytochrome P450 2C9 Proteins 0.000 title claims description 12
- 230000035772 mutation Effects 0.000 title description 40
- 125000003729 nucleotide group Chemical group 0.000 claims description 70
- 239000002773 nucleotide Substances 0.000 claims description 67
- 108700028369 Alleles Proteins 0.000 claims description 56
- 230000000295 complement effect Effects 0.000 claims description 50
- 239000011324 bead Substances 0.000 claims description 20
- 238000002493 microarray Methods 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 13
- 238000012408 PCR amplification Methods 0.000 claims description 9
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 claims 15
- 230000000052 comparative effect Effects 0.000 claims 2
- 108020004414 DNA Proteins 0.000 description 36
- 239000000523 sample Substances 0.000 description 32
- 238000001514 detection method Methods 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 23
- 238000003205 genotyping method Methods 0.000 description 12
- 239000004005 microsphere Substances 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000002372 labelling Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 4
- 102100029075 Exonuclease 1 Human genes 0.000 description 4
- 108010090804 Streptavidin Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 108010012052 cytochrome P-450 CYP2C subfamily Proteins 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007403 mPCR Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 101150082072 14 gene Proteins 0.000 description 1
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 101150053096 CYP2C9 gene Proteins 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 101000919359 Homo sapiens Cytochrome P450 2C9 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58361904P | 2004-06-30 | 2004-06-30 | |
| US60/583,619 | 2004-06-30 | ||
| PCT/CA2005/000998 WO2006002525A1 (en) | 2004-06-30 | 2005-06-30 | Method of detecting mutations in the gene encoding cytochrome p450-2c9 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005259786A1 AU2005259786A1 (en) | 2006-01-12 |
| AU2005259786B2 true AU2005259786B2 (en) | 2011-03-10 |
Family
ID=35782442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005259786A Ceased AU2005259786B2 (en) | 2004-06-30 | 2005-06-30 | Method of detecting mutations in the gene encoding cytochrome P450-2C9 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090099030A1 (enExample) |
| EP (1) | EP1781812A4 (enExample) |
| JP (1) | JP2008504825A (enExample) |
| AU (1) | AU2005259786B2 (enExample) |
| CA (1) | CA2571817A1 (enExample) |
| WO (1) | WO2006002525A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1781811B1 (en) * | 2004-06-30 | 2010-06-23 | Luminex Molecular Diagnostics, Inc. | Method of detecting mutations in the gene encoding cytochrome p450-2d6 |
| US20080248466A1 (en) * | 2004-07-30 | 2008-10-09 | Tm Bioscience Pgx Inc. | Method Of Detecting Mutations In The Gene Encoding Cytochrome P450-2C19 |
| GB0506866D0 (en) | 2005-04-05 | 2005-05-11 | Rolls Royce Plc | A fuel cell arrangement |
| JPWO2008066163A1 (ja) * | 2006-11-30 | 2010-03-11 | アークレイ株式会社 | Ｃｙｐ２ｃ９遺伝子増幅用プライマーセット、それを含むｃｙｐ２ｃ９遺伝子増幅用試薬およびその用途 |
| CA2704487A1 (en) * | 2007-11-02 | 2009-06-18 | Luminex Molecular Diagnostics, Inc. | One-step target detection assay |
| WO2009128730A1 (en) * | 2008-01-25 | 2009-10-22 | Patrick Gladding | Methods and compositions for the assessment of drug response |
| CN102686728B (zh) | 2009-06-29 | 2018-09-18 | 卢米耐克斯公司 | 具有发夹构象的嵌合引物及其使用方法 |
| TWI600766B (zh) | 2012-08-09 | 2017-10-01 | 財團法人工業技術研究院 | 用於偵測一目標核苷酸序列中之一特定區域的一突變及／或多形性的套組 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000012757A1 (en) * | 1998-08-28 | 2000-03-09 | Sangtec Molecular Diagnostics Ab | A method for measuring a patient's ability to metabolise certain drugs |
| WO2000047766A1 (en) * | 1999-02-11 | 2000-08-17 | Astrazeneca Ab | Method for detecting variant nucleotides using arms multiplex amplification |
| WO2004018707A2 (de) * | 2002-08-15 | 2004-03-04 | Biotez Berlin-Buch Gmbh | Verfahren zum nachweis von einzelnukleotid-polymorphismen (snp) in genen des arzneimittelmetabolismus und testkit zur durchführung des verfahrens |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4851331A (en) * | 1986-05-16 | 1989-07-25 | Allied Corporation | Method and kit for polynucleotide assay including primer-dependant DNA polymerase |
| US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| US5605662A (en) * | 1993-11-01 | 1997-02-25 | Nanogen, Inc. | Active programmable electronic devices for molecular biological analysis and diagnostics |
| JP2001017185A (ja) * | 1999-03-19 | 2001-01-23 | Otsuka Pharmaceut Co Ltd | 薬物代謝酵素遺伝子多型の簡易検出法 |
| US6287778B1 (en) * | 1999-10-19 | 2001-09-11 | Affymetrix, Inc. | Allele detection using primer extension with sequence-coded identity tags |
| EP2327794A3 (en) * | 2001-01-25 | 2011-09-14 | TM Bioscience Corporation | Polynucleotides for use as tags and tag complements, manufacture and use thereof |
| JP4781628B2 (ja) * | 2001-12-05 | 2011-09-28 | センス プロテオミック リミテッド | 対立遺伝子改変体のためのタンパク質アレイおよびその使用 |
| WO2004025244A2 (en) * | 2002-09-16 | 2004-03-25 | Sense Proteomic Limited | Protein arrays and uses thereof |
| US20080248466A1 (en) * | 2004-07-30 | 2008-10-09 | Tm Bioscience Pgx Inc. | Method Of Detecting Mutations In The Gene Encoding Cytochrome P450-2C19 |
-
2005
- 2005-06-30 CA CA002571817A patent/CA2571817A1/en not_active Abandoned
- 2005-06-30 JP JP2007519574A patent/JP2008504825A/ja active Pending
- 2005-06-30 AU AU2005259786A patent/AU2005259786B2/en not_active Ceased
- 2005-06-30 WO PCT/CA2005/000998 patent/WO2006002525A1/en not_active Ceased
- 2005-06-30 EP EP05761962A patent/EP1781812A4/en not_active Withdrawn
- 2005-06-30 US US11/631,200 patent/US20090099030A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000012757A1 (en) * | 1998-08-28 | 2000-03-09 | Sangtec Molecular Diagnostics Ab | A method for measuring a patient's ability to metabolise certain drugs |
| WO2000047766A1 (en) * | 1999-02-11 | 2000-08-17 | Astrazeneca Ab | Method for detecting variant nucleotides using arms multiplex amplification |
| WO2004018707A2 (de) * | 2002-08-15 | 2004-03-04 | Biotez Berlin-Buch Gmbh | Verfahren zum nachweis von einzelnukleotid-polymorphismen (snp) in genen des arzneimittelmetabolismus und testkit zur durchführung des verfahrens |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1781812A1 (en) | 2007-05-09 |
| US20090099030A1 (en) | 2009-04-16 |
| AU2005259786A1 (en) | 2006-01-12 |
| WO2006002525A1 (en) | 2006-01-12 |
| EP1781812A4 (en) | 2008-10-15 |
| CA2571817A1 (en) | 2006-01-12 |
| JP2008504825A (ja) | 2008-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7879543B2 (en) | Method of detecting mutations associated with thrombosis | |
| EP2314680B1 (en) | Method for amplification of target nucleic acid sequence, method for detection of mutation by using the method, and reagents for use in the methods | |
| JP2008200050A (ja) | 核酸配列変異を検出するための方法とオリゴヌクレオチド | |
| JP2007525998A (ja) | 脆弱ｘ症候群などのｓｔｒｐの検出 | |
| Voisey et al. | SNP technologies for drug discovery: a current review | |
| Daca-Roszak et al. | EurEAs_Gplex—a new SNaPshot assay for continental population discrimination and gender identification | |
| AU2005259786B2 (en) | Method of detecting mutations in the gene encoding cytochrome P450-2C9 | |
| CN101622363A (zh) | 用于检测jak2基因的突变的探针及其用途 | |
| AU2005259787B2 (en) | Method of detecting mutations in the gene encoding cytochrome P450-2D6 | |
| AU2005266805B2 (en) | Method of detecting mutations in the gene encoding Cytochrome P450-2C19 | |
| EP1307590A1 (en) | Diagnostic polymorphisms for the tgf-beta1 promoter | |
| CA2294572A1 (en) | Genetic compositions and methods | |
| CN118562930A (zh) | 一种基于液态芯片的snp检测方法 | |
| JP2005245273A (ja) | アルデヒド脱水素酵素遺伝子多型の簡易検出方法および検出用試薬 | |
| JP2010246400A (ja) | 多型の識別方法 | |
| JP2001046085A (ja) | 血色素症遺伝子を増幅して検出するためのオリゴヌクレオチド | |
| JP2005176601A (ja) | Ｃｙｐ２ｄ６変異遺伝子 | |
| JP2005027519A (ja) | ヒトチトクロームｐ４５０２ａ６遺伝子多型の簡易検出方法および検出用試薬 | |
| JP2005198525A (ja) | グルタチオンｓ−トランスフェラーゼ遺伝子多型の検出方法および検出用キット |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |